newsfilter
← Latest News
PR Newswire·

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update

—Total Company Revenues of $524.4 Million for the Third Quarter of 2026——BRINSUPRI® (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second Quarter of